Sean Fu is an experienced leader and proven entrepreneur. Sean was co-founder and CEO of RVAC Medicines, an mRNA company established in 2021, raised $170 million and successfully brought two COVID vaccines into clinical study.
Prior to founding RVAC, Sean was Group VP and head of International R&D of Luye Pharma, overseeing organizations in Boston, Princeton, Germany, Switzerland and Japan. He was also the founding CEO of GeneLeap, a Luye subsidiary company focusing on DNA and RNA therapeutics.
Previously, Sean worked at Merck & Co. for 15 years with increasing responsibilities covering R&D, business development, and finance. He managed the finances of a $300 million late-stage clinical portfolio and led the integration of global R&D network after the landmark $42 billion merger between Merck and Schering-Plough.
His numerous honors included Merck & Co’s highest award for R&D innovation—the Best Business Value Award (2005); The Ohio State University William Oxley Thompson Alumni Award (2006), College of Engineering Distinguished Alumni Award (2022) and the Materials Research Society (MRS) Gold Award for Research (2000).
Sean earned a PhD in materials science and engineering from the Ohio State University, and an MBA from Wharton School of University of Pennsylvania.